• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二巯基丁二酸钠预防环磷酰胺和异环磷酰胺的尿路毒性作用(初步报告)(作者译)

[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].

作者信息

Brock N, Stekar J

出版信息

Arzneimittelforschung. 1982;32(5):486-7.

PMID:6809014
Abstract

Sodium 2-mercaptoethane sulfonate (mesna, Uromitexan) is oxidized in the organism of rats to 2,2'-dithiodi-(ethane sodium sulfonate) (dimesna). Dimesna is partially reduced to the mercapto compound mesna (kidneys); both compounds are eliminated via the urine. Even after administration of dimesna mesna can be detected in the urine. Accordingly dimesna also proved to be an effective antidote against the urotoxic actions of cyclophosphamide and ifosfamide.

摘要

2-巯基乙烷磺酸钠(美司钠,Uromitexan)在大鼠体内被氧化为2,2'-二硫代二(乙烷磺酸钠)(二巯基丁二酸钠)。二巯基丁二酸钠部分还原为巯基化合物美司钠(肾脏);两种化合物均通过尿液排出。即使给予二巯基丁二酸钠后,尿液中仍可检测到美司钠。因此,二巯基丁二酸钠也被证明是一种有效的抗环磷酰胺和异环磷酰胺尿路毒性作用的解毒剂。

相似文献

1
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].二巯基丁二酸钠预防环磷酰胺和异环磷酰胺的尿路毒性作用(初步报告)(作者译)
Arzneimittelforschung. 1982;32(5):486-7.
2
Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.通过提高氧氮磷杂环类细胞抑制剂的选择性进行局部解毒来预防泌尿毒性副作用。
IARC Sci Publ. 1986(78):269-79.
3
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).通过额外给予尿路保护剂2-巯基乙烷磺酸钠(美司钠)和2,2'-二硫代双乙烷磺酸钠(二巯基丁二酸钠)预防环磷酰胺治疗大鼠的膀胱肿瘤。
Cancer. 1983 Feb 15;51(4):606-9. doi: 10.1002/1097-0142(19830215)51:4<606::aid-cncr2820510409>3.0.co;2-s.
4
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.巯基化合物对尿毒性氮杂磷类化合物的解毒作用。
J Cancer Res Clin Oncol. 1981;100(3):311-20. doi: 10.1007/BF00410691.
5
Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.二硫代双巯基乙烷磺酸盐(美司钠)不能预防异环磷酰胺和环磷酰胺的代谢产物对LLC-PK1细胞造成的细胞损伤。
Pediatr Nephrol. 1994 Aug;8(4):458-65. doi: 10.1007/BF00856531.
6
[Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].[针对氧氮磷啶衍生物环磷酰胺、异环磷酰胺和曲磷胺尿路毒性作用的解毒剂]
Naturwissenschaften. 1979 Jan;66(1):60-1. doi: 10.1007/BF00369371.
7
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.接受分次静脉注射异环磷酰胺及同时应用美司钠治疗的患者尿液中异环磷酰胺、4-羟基异环磷酰胺、3-和2-去氯乙基异环磷酰胺、美司钠及二巯基丁二酸钠的排泄情况。
Cancer Chemother Pharmacol. 1997;39(5):431-9. doi: 10.1007/s002800050594.
8
The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.美司钠和二巯基丁二酸钠与人红细胞中硫酸盐交换的相互作用。
Arzneimittelforschung. 1986 Apr;36(4):763-5.
9
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).氮杂磷三环类细胞抑制剂的尿路毒性及其预防研究——III. 2-巯基乙烷磺酸钠(美司钠)的作用概况。
Eur J Cancer Clin Oncol. 1982 Dec;18(12):1377-87. doi: 10.1016/0277-5379(82)90143-2.
10
[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].[2-巯基乙烷磺酸钠(美司钠)预防膀胱肿瘤形成。实验研究及临床结果]
Urologe A. 1984 Sep;23(5):291-6.

引用本文的文献

1
Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.低分子量硫醇解毒的药代动力学及作用机制
J Cancer Res Clin Oncol. 1984;108(1):87-97. doi: 10.1007/BF00390979.
2
Bladder carcinoma following cyclophosphamide therapy. A case report.环磷酰胺治疗后发生的膀胱癌。病例报告。
Int Urol Nephrol. 1985;17(2):139-42. doi: 10.1007/BF02082484.